Inventor · disambiguated record
Hendrik Knoetgen
Also filed as: KNOETGEN HENDRIK
15 granted patents·18 pending applications·139 citations·filing 2007–2021
91Inventor score
Top patents by PatentIndex Score
33 records- 0194US8771988B2Protein expression from multiple nucleic acidsGOEPFERT ULRICH·Filed 2008·Granted Jul 8, 2014·36 cites·11 claims
- 0293US8003099B2Antibodies against human IL17 and uses thereofROCHE PALO ALTO LLC·Filed 2009·Granted Aug 23, 2011·44 cites·17 claims
- 0391US10501521B2Disulfide-linked multivalent MHC class I comprising multi-function proteinsHOFFMANN LA ROCHE·Filed 2013·Granted Dec 10, 2019·39 cites·9 claims
- 0489US7625996B2Method for the production of conjugates of insulin-like growth factor-1 and poly(ethylene glycol)HOFFMANN LA ROCHE·Filed 2007·Granted Dec 1, 2009·14 cites·9 claims
- 0582US8552158B2Method for the production of insulin-like growth factor-1FISCHER STEPHAN·Filed 2007·Granted Oct 8, 2013·2 cites·4 claims
- 0680US8093006B2Antibodies against human tweak and uses thereofBAEHNER MONIKA·Filed 2010·Granted Jan 10, 2012·4 cites·10 claims
- 0772US2022089769A1Removal of target cells by circulating virus-specific cytotoxic t-cells using mhc class i comprising complexesHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 0867US9428766B2Protein expression from multiple nucleic acidsHOFFMANN LA ROCHE·Filed 2014·Granted Aug 30, 2016·0 cites·1 claims
- 0967US2020157239A1Removal of target cells by circulating virus-specific cytotoxic t-cells using mhc class i comprising complexesHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 1067US2019233842A1Protein expression from multiple nucleic acidsHOFFMANN LA ROCHE·Filed 2018·Application pending·0 cites
- 1166US2021054083A1Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptidesHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 1265US10882910B2Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptidesHOFFMANN LA ROCHE·Filed 2018·Granted Jan 5, 2021·0 cites·17 claims
- 1365US2010035817A1Method for the production of conjugates of insulin-like growth factor-1 and poly(ethylene glycol)FISCHER STEPHAN·Filed 2009·Application pending·0 cites
- 1462US2017166923A1Protein expression from multiple nucleic acidsHOFFMANN LA ROCHE·Filed 2016·Application pending·0 cites
- 1561US2021024952A1Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptidesHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 1660US9963511B2Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptidesHOFFMANN LA ROCHE·Filed 2012·Granted May 8, 2018·0 cites·28 claims
- 1757US8883976B2Antibodies against human tweak and uses thereofBAEHNER MONIKA·Filed 2012·Granted Nov 11, 2014·0 cites·4 claims
- 1857US8476232B2Method for the production of conjugates of insulin-like growth factor-1 and poly(ethylene glycol)FISCHER STEPHAN·Filed 2012·Granted Jul 2, 2013·0 cites·1 claims
- 1956US2013011394A1Complexes comprising mhc class i fusion polypeptides and antigen-specific antibodies and methods of useHOFFMANN LA ROCHE·Filed 2012·Application pending·0 cites
- 2055US8852887B2Antibodies against human tweak and uses thereofBAEHNER MONIKA·Filed 2011·Granted Oct 7, 2014·0 cites·16 claims
- 2154US2022073630A1A peptide-mhc-i-antibody fusion protein for therapeutic use in a patient with amplified immune responseHOFFMANN LA ROCHE·Filed 2019·Application pending·0 cites
- 2253US2016362500A1Removal of target cells by circulating virus-specific cytotoxic T-cells using MHC class I comprising complexesHOFFMANN LA ROCHE·Filed 2016·Application pending·0 cites
- 2352US2016208284A1Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptidesHOFFMANN LA ROCHE·Filed 2012·Application pending·0 cites
- 2449US2010210547A1Method for the production of conjugates of insulin-like growth factor-1 and poly(ethylene glycol)FISCHER STEPHAN·Filed 2010·Application pending·0 cites
- 2548US2019169309A1Removal of cancer cells by circulating virus-specific cytotoxic t-cells using cancer cell targeted mhc class 1 compromising multi-function proteinsROCHE GLYCART AG·Filed 2018·Application pending·0 cites
- 2647US8314225B2Heavy chain mutant leading to improved immunoglobulin productionGOEPFERT ULRICH·Filed 2008·Granted Nov 20, 2012·0 cites·20 claims
- 2746US9187564B2Antibodies against human TWEAK and uses thereofBAEHNER MONIKA·Filed 2011·Granted Nov 17, 2015·0 cites·11 claims
- 2846US2015038354A1Full length antibody display system for eukaryotic cells and its useHOFFMANN LA ROCHE·Filed 2014·Application pending·0 cites
- 2945US2016083477A1Removal of Cancer Cells by Circulating Virus-Specific Cytotoxic T-Cells Using Cancer Cell Targeted MHC Class 1 Compromising Multi-Function ProteinsROCHE GLYCART AG·Filed 2015·Application pending·0 cites
- 3045US2016168253A1Therapeutic fusion proteinHOFFMANN LA ROCHE·Filed 2014·Application pending·0 cites
- 3141US8207307B2Antibodies against human CCN1 and uses thereofKNOETGEN HENDRIK·Filed 2010·Granted Jun 26, 2012·0 cites·6 claims
- 3239US2013195844A1Antibodies against human il17 and uses thereofAUER JOHANNES·Filed 2011·Application pending·0 cites
- 3336US2012258112A1Antibodies against human ccn1 and uses thereofKNOETGEN HENDRIK·Filed 2012·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Hendrik Knoetgen files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →